Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeppe Zacho

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of the National Cancer Institute|January 9, 2010
C-reactive protein and the risk of cancer: a mendelian randomization studyKristine H Allin, Børge G Nordestgaard, Jeppe Zacho, et al.
Diabetes, Obesity & Metabolism|May 12, 2018
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetesKristin C C Petri, Steen H Ingwersen, Anne Flint, et al.
Diabetes, Obesity & Metabolism|June 7, 2019
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an exampleVanita R Aroda, Trine Saugstrup, John B Buse, et al.
The New England Journal of Medicine|October 31, 2008
Genetically elevated C-reactive protein and ischemic vascular diseaseJeppe Zacho, Anne Tybjaerg-Hansen, Jan Skov Jensen, et al.
Ugeskrift for Laeger|June 5, 2009
[C-reactive protein and risk of ischaemic vascular and cerebrovascular disease--secondary publication]Jeppe Zacho, Anne Tybjaerg-Hansen, Jan Skov Jensen, et al.
Diabetes, Obesity & Metabolism|August 9, 2017
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetesYutaka Seino, Yasuo Terauchi, Takeshi Osonoi, et al.
Hypertension (Dallas, Tex. : 1979)|May 28, 2009
Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotypeNicholas J Timpson, Roger Harbord, George Davey Smith, et al.
Diabetes, Obesity & Metabolism|June 5, 2018
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programmeJ Hans DeVries, Cyrus Desouza, Srikanth Bellary, et al.
Diabetes Care|July 21, 2018
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without MetforminIldiko Lingvay, Cyrus V Desouza, Katarina S Lalic, et al.
Journal of the American College of Cardiology|August 28, 2010
Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general populationSarah C W Marott, Børge G Nordestgaard, Jeppe Zacho, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of the National Cancer Institute|January 9, 2010
C-reactive protein and the risk of cancer: a mendelian randomization studyKristine H Allin, Børge G Nordestgaard, Jeppe Zacho, et al.
Diabetes, Obesity & Metabolism|May 12, 2018
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetesKristin C C Petri, Steen H Ingwersen, Anne Flint, et al.
Diabetes, Obesity & Metabolism|June 7, 2019
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an exampleVanita R Aroda, Trine Saugstrup, John B Buse, et al.
The New England Journal of Medicine|October 31, 2008
Genetically elevated C-reactive protein and ischemic vascular diseaseJeppe Zacho, Anne Tybjaerg-Hansen, Jan Skov Jensen, et al.
Ugeskrift for Laeger|June 5, 2009
[C-reactive protein and risk of ischaemic vascular and cerebrovascular disease--secondary publication]Jeppe Zacho, Anne Tybjaerg-Hansen, Jan Skov Jensen, et al.
Diabetes, Obesity & Metabolism|August 9, 2017
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetesYutaka Seino, Yasuo Terauchi, Takeshi Osonoi, et al.
Hypertension (Dallas, Tex. : 1979)|May 28, 2009
Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotypeNicholas J Timpson, Roger Harbord, George Davey Smith, et al.
Diabetes, Obesity & Metabolism|June 5, 2018
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programmeJ Hans DeVries, Cyrus Desouza, Srikanth Bellary, et al.
Diabetes Care|July 21, 2018
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without MetforminIldiko Lingvay, Cyrus V Desouza, Katarina S Lalic, et al.
Journal of the American College of Cardiology|August 28, 2010
Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general populationSarah C W Marott, Børge G Nordestgaard, Jeppe Zacho, et al.
Pageof 3